Ent-Tadalafil is primarily investigated for its potential therapeutic applications, particularly in the field of urology and cardiovascular health. It is studied for its ability to inhibit phosphodiesterase type 5 (PDE5), which plays a role in regulating blood flow. This mechanism suggests its potential use in treating conditions like erectile dysfunction and pulmonary arterial hypertension, similar to its enantiomer, Tadalafil. Additionally, research explores its efficacy in managing benign prostatic hyperplasia, as it may help relax smooth muscles in the prostate and bladder, improving urinary symptoms. Its unique stereochemistry is also of interest in pharmacological studies to understand the impact of enantiomeric differences on drug activity and side effects.